Tag: Goserelin

10. August 2022

AMW Strengthens Management Team to Support the Company’s Growth Strategy

AMW GmbH, a specialty pharmaceutical company focused on innovative sustained-release drug delivery systems, today announced that it has strengthened its management team with the appointment of experienced professionals to head its Research & Development (R&D), Quality and Human Resources (HR) departments.

13. July 2022

Additional Market Authorizations for AMW’s Goserelin Implant for the Treatment of Hormone-Dependent Tumors in the EU and Central America

AMW GmbH, a specialty pharmaceutical company focused on innovative sustained-release drug delivery systems, today announced that its goserelin implant has received market authorization in one country each in the European Union and Central America. . AMW’s goserelin implant is the only generic implant version approved to date for AstraZeneca’s branded Zoladex®1. Goserelin enables symptomatic therapy of hormone-dependent tumors, such as prostate or breast cancer, as well as certain gynecological disorders. AMW’s goserelin implant is now available to patients in around 30 countries worldwide as a cost-effective alternative therapy.

19. October 2021

AMW signs License and Supply Agreement for Commercialization of its Goserelin and Leuprorelin implants in Israel

AMW GmbH, a specialty pharmaceutical company focused on innovative drug delivery systems, today announced that it has entered into license and supply agreements (LSA) with an undisclosed partner for the commercialization of its goserelin and leuprorelin implants in the country of Israel.

22. May 2021

AMW signs License and Supply Agreement for Commercialization of Goserelin Implant in a LATAM Country

AMW GmbH, a specialty pharmaceutical company focused on innovative drug delivery systems, today announces that it has entered into a license and supply agreement (LSA) with an undisclosed partner for the commercialization of its goserelin implant in a relevant LATAM country. AMW’s new LATAM partner is active and highly experienced in the registration and commercialization of pharmaceutical products and will help to bring improved medication to patients.

4. November 2015

For the biodegradable goserelin implants 3.6 mg and 10.8 mg developed by AMW GmbH and clinically tested, the national approval was obtained today as part of a DCP procedure.

The products are characterized by innovative applicators. Handling is easier, misapplications and painful injections are avoided.

2. January 2014

In January 2014, AMW GmbH was able to conclude a semi-exclusive license and supply contract for its biodegradable goserelin implants with a multinational pharmaceutical company.

The contract applies to Southeast Asia, including China, Eastern Europe, Russia and some Western European countries. The agreements contain down payment payments of up to € 10 million, license payments in the double-digit percentage range, and an exclusive delivery agreement for AMW. The partner company will carry out further clinical developments for the contract area.